Table 1.
Patient characteristics by treatment group (randomised population)11
| Dacarbazine (n=338) | Vemurafenib (n=337) | |
|---|---|---|
| Median age (years) | 52·5 (43·0–62·0) | 56·0 (47·0–65·0) |
|
| ||
| Male sex | 181 (54%) | 200 (59%) |
|
| ||
| ECOG PS | ||
| 0 | 230 (68%) | 229 (68%) |
| 1 | 108 (32%) | 108 (32%) |
|
| ||
| Stage | ||
| Unresectable IIIc | 13 (4%) | 20 (6%) |
| M1a | 40 (12%) | 34 (10%) |
| M1b | 65 (19%) | 62 (18%) |
| M1c | 220 (65%) | 221 (66%) |
| LDH >ULN | 142 (42%) | 142 (42%) |
Data are number of patients (%) or median IQR. ECOG PS=Eastern Cooperative Oncology Group performance status. LDH=lactate dehydrogenase. ULN=upper limit of normal. Reprinted with permission from Massachusetts Medical Society, who own the copyright.